Search the Newsreel

Behavioral Patterns of BCRX and Institutional Flows

The article analyzes Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), highlighting a weak near and mid-term sentiment but a positive long-term outlook. It details AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, and provides multi-timeframe signal analysis with support and resistance …

BioCryst Pharmaceuticals (BCRX) Faces A Valuation Test, Is The Undervalued Case Convincing?

BioCryst Pharmaceuticals (BCRX) stock has seen a recent decline after a strong year, leading to questions about its valuation. Despite being 58.6% undervalued according to a popular narrative with a fair value of $21.30 against its current $8.81, the company faces pressure points like …

ETFs Investing in BioCryst Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of BioCryst Pharmaceuticals, Inc. (BCRX). The ETFs are sorted by their market value and provide details such as issuer, management style, expense ratio, assets under management (AUM), and 3-year NAV total return. The …

BioCryst Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) generated $874.84 million in revenue last year, primarily from its Oral Small-molecule and Injectable Protein Therapeutics segment. This represents a significant increase from $450.71 million in the previous year. The United States was the largest contributor to revenue, accounting …

BioCryst Pharmaceuticals Inc (BCRX) Institutional Confidence

BioCryst Pharmaceuticals Inc (BCRX) has a high institutional shareholding score of 10.00, ranking 1st in its industry, despite a recent 10.51% quarter-over-quarter decrease in institutional shareholding proportion. The largest institutional shareholder is James Simons, and notable institutional holders include BlackRock, RA Capital Management, and …

BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday

BCRX|BioCryst Pharmaceuticals Inc|Price:9.609|Chg%:-0.131

This article provides a comprehensive stock analysis of BioCryst Pharmaceuticals Inc (BCRX), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes strong institutional ownership, a consensus "Buy" rating from analysts with a …

BioCryst Pharmaceuticals Inc (BCRX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioCryst Pharmaceuticals Inc (BCRX), noting its current valuation score of 8.70, ranking 95th in its industry. It highlights the company's P/E ratio of -5.56 and states that relevant data for P/B, P/S, and P/CF ratios have not …

Rice Hall James & Associates LLC Acquires 325,959 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Rice Hall James & Associates LLC significantly increased its stake in BioCryst Pharmaceuticals by 17.1% in the first quarter, adding 325,959 shares to own a total of 2,230,105 shares valued at approximately $21.2 million. Institutional ownership of BioCryst remains high at 85.88%, with numerous …

BioCryst Pharmaceuticals Inc (BCRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioCryst Pharmaceuticals Inc (BCRX), listing its major shareholders and institutional holdings. It provides a breakdown of investor types, institutional shareholding over several quarters, and recent shareholder activities. The data highlights significant investors like BlackRock, RA Capital Management, …

BioCryst Pharmaceuticals, Inc. Revenue Breakdown – MUN:BO1

BioCryst Pharmaceuticals, Inc. (MUN:BO1) reported a total revenue of €744.85 million last year, primarily driven by its Oral Small-molecule and Injectable Protein Therapeutics segment. The United States was the largest geographical contributor, accounting for €467.24 million of the revenue. This represents a significant increase …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares passed above their 200-day moving average on Thursday, trading as high as $9.48. The stock has a consensus "Moderate Buy" rating from analysts with an average target price of $20.80, despite the company reporting a wider-than-expected quarterly loss. Institutional investors …

Biocryst Pharmaceuticals Inc. (BCRX) Fundamental & Financial Data

This article provides fundamental and financial data for Biocryst Pharmaceuticals Inc. (BCRX), including its current stock price, market capitalization, dividend yield, and analyst ratings. It also highlights recent news like the appointment of a new Chief Scientific Officer and mentions that Wall Street analysts …

BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock price, analysis, news, and trading ideas for BioCryst Pharmaceuticals Inc. (BCRX). It includes current market data such as stock price, market cap, volume, 52-week high/low, PE ratio, and recent news headlines related to the company and the biotech …

BCRX Q2'26 Earnings: revenue estimate is 183.28M USD

BioCryst Pharmaceuticals, Inc. (BCRX) is scheduled to announce its Q2'26 earnings on July 30. Analysts estimate revenue to be $183.28 million and earnings per share (EPS) at $0.15 for the quarter. The article provides a table of past reported and estimated revenue and EPS …

(BCRX) Movement Within Algorithmic Entry Frameworks

The article details an algorithmic analysis of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), identifying divergent sentiment across various time horizons and an exceptional 48.0:1 risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, …

How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals

BioCryst Pharmaceuticals recently appointed David W. Jenkins as its first Chief Scientific Officer to lead efforts in external innovation and partnerships for rare disease therapies. This move signals BioCryst's commitment to expanding its pipeline beyond its primary drug, ORLADEYO, though near-term focus remains on …

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the results and provide a corporate update. …

BioCryst schedules a look at second-quarter results for Aug. 5

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. The company's prior earnings-date announcements …

Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story?

BioCryst Pharmaceuticals (BCRX) has appointed David W. Jenkins as its new Chief Scientific Officer, a move generating interest among investors. The company's stock currently trades at US$9.29, with a mixed performance of 23.87% year-to-date but a 46.14% decline over five years. A common narrative …

BioCryst Pharmaceuticals (BCRX) Proxy filing Summary

BioCryst Pharmaceuticals (BCRX) has announced details of its upcoming Annual Meeting scheduled for June 11, 2026. Shareholders will vote on the election of three directors, ratification of Ernst & Young LLP as auditors, an advisory vote on executive compensation, and approval of an amended …

BioCryst Pharmaceuticals (BCRX) Q4 2025 earnings summary

BioCryst Pharmaceuticals achieved record revenue and its first full-year profitability in 2025, driven by the strong performance of ORLADEYO and strategic expansions. The company reported $601.8 million in ORLADEYO revenue and $874.8 million in total revenues, with GAAP operating profit of $341 million. BioCryst …

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?

Penguin Solutions (PENG), Arista Networks (ANET), and Biocryst Pharmaceuticals (BCRX) all reached 52-week highs due to positive market sentiment and various catalysts. PENG benefited from increased analyst price targets driven by AI demand, ANET saw optimism for its cloud networking solutions and AI infrastructure, …

Citizens reiterates BioCryst stock rating on Orladeyo revenue outlook

Citizens maintained its Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a $28 price target, citing Orladeyo revenue projections. The firm forecasts $160 million in Orladeyo revenues for Q2 2026, aligning with consensus, and $648 million for the full year 2026, slightly above …

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BioCryst Pharmaceuticals, Inc. announced the appointment of David W. Jenkins, MA, PhD, as its new Chief Scientific Officer, effective immediately. In this role, Dr. Jenkins will focus on building and leading a research team to leverage external innovation and partnerships to accelerate the delivery …

BioCryst Pharmaceuticals’ SWOT analysis: stock gains ground on pediatric approval

BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?

Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up

BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

BioCryst drug sales hit $148M as Europe licensing deal brings $70M

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals earnings loom amid HAE market battle

Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains

BioCryst Stock Surges After Strong Q4 Earnings and Astria Acquisition

BioCryst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary